News

Potential NIH and FDA cuts could lower the number of new drugs that come to market in the next three decades, according to a ...
George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and ...
The House and Senate are taking far different approaches to next year's appropriations, but neither chamber has fully ...
Loss of support staff has slowed critical investigations of drug manufacturers. Little relief has materialized.
Last Monday, the U.S. Department of Health and Human Services (HHS) finalized 10,000 layoffs across federal health agencies, including the National Institutes of Health (NIH), U.S. Food and Drug ...
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...
The U.S. Food and Drug Administration named ex-biotech exec George Tidmarsh as its chief drug regulator. FDA Commissioner ...
Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the ...
"What's so beautiful about not helping people?" asked one participant in the Veteran's Alcoholic Rehabilitation Program. "Why ...
The Food and Drug Administration (FDA) can maintain its high bar for safety and efficacy, and also cut the waste and ...
Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...